How PIPEs finally unblocked biotech’s funding flows

The first quarter of 2024 has seen biotech’s funding drought broken, largely through private investment in public equity (PIPE) deals. In this episode of Pathfinders in Biopharma, three members of RBC’s biotech investment banking team look at the impact of PIPEs’ success on the sector and consider how long it can last – and why it has not been universally welcomed.

Episode metadata supplied by the publisher feed · Published Mar 29, 2024

Embed this episode

Attribution link and audio player

NOW PLAYING

How PIPEs finally unblocked biotech’s funding flows

0:00 17:36

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of Pathfinders in Biopharma?

This episode is 17 minutes long.

When was this Pathfinders in Biopharma episode published?

This episode was published on March 29, 2024.

Can I download this Pathfinders in Biopharma episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!